Tadaaki Taniguchi - Concepedia

Author

Tadaaki Taniguchi

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

T TANIGUCHI, T Taniguchi, T. Taniguchi, TADAAKI TANIGUCHI, TM Taniguchi, Tadaaki Taniguchi

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Hyogo Medical University Tokyo Metropolitan Komagome Hospital The University of Tokyo Ono Pharmaceutical (Japan)

About

Tadaaki Taniguchi is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	870
2	Health Sciences	3	3	260
3	Diabetes	3	3	149
4	Public Health	1	1	41
5	Social Sciences	1	1	20

Tadaaki Taniguchi

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Yutaka Yamamoto, Masakazu Toi, Shinichi Kondo, PubMed Normal ControlsBreast OncologyImmunologyPathologyCancer Patients	1996	244
Quantitative analysis of vascular endothelial growth factor in primary breast cancer Masakazu Toi, Shinichi Kondo, Hideo Suzuki, Cancer	1996	196
Expression of platelet‐derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer Masakazu Toi, Seigo Hosnina, Tadaaki Taniguchi, International Journal of Cancer	1995	162
Serum concentrations of hepatocyte growth factor in breast cancer patients. Tadaaki Taniguchi, M. Toi, K Inada, PubMed Breast OncologySerum Hgf LevelPathologyHgf LevelTumor Biology	1995	103
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double‐blind trial Yasuhiko Iwamoto, Naoko Tajima, Takashi Kadowaki, Diabetes Obesity and Metabolism	2010	100
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus Yasuhiko Iwamoto, Tadaaki Taniguchi, Kenji Nonaka, Endocrine Journal Dose-ranging EfficacyJapanese PatientsDiabetes ManagementDiabetesPharmacology	2010	97
Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Masakazu Toi, Tadaaki Taniguchi, Takayuki Ueno, PubMed Breast OncologySerum Hgf LevelPathologyPrimary Breast CancerHgf Level	1998	88
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study Shinji Uchida, Tadaaki Taniguchi, Takafumi Shimizu, Journal of Bone and Mineral Metabolism Bone DiseaseBone HealthMedicineAlendronate 35Therapeutic Effects	2005	71
Increase in the circulating level of hepatocyte growth factor in gastric cancer patients Tadaaki Taniguchi, M Kitamura, K Arai, British Journal of Cancer Hepatocyte Growth FactorHepatologyGastrointestinal OncologyMedicineLiver Physiology	1997	69
Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control Naoko Tajima, Takashi Kadowaki, Masato Odawara, Diabetology International Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyGlimepiride Therapy	2011	41

Page 1